Metacrine to Present at 2021 Canaccord Genuity Growth Conference

Rhea-AI Summary

Metacrine, a clinical-stage biopharmaceutical company (NASDAQ:MTCR), announced that its CEO, Preston Klassen, will present at the 2021 Canaccord Genuity Growth Conference on August 12, 2021, at 12:30 p.m. ET. A live webcast will be available for viewing, with a replay accessible for 90 days post-conference. Metacrine focuses on developing therapies for liver and gastrointestinal diseases, leveraging its proprietary farnesoid X receptor (FXR) platform. Its lead candidates, MET409 and MET642, are under investigation for treating NASH.

SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that Preston Klassen, M.D., MHS, president and chief executive officer, will present virtually at the 2021 Canaccord Genuity Growth Conference at 12:30 p.m. ET on Thursday, August 12, 2021.

A live webcast of the presentation will be available at https://investors.metacrine.com/events-and-presentations.   A replay of the webcast will be archived for 90 days following the conference.  

About Metacrine

Metacrine, Inc. is a clinical-stage biopharmaceutical company building a pipeline of differentiated therapies to treat liver and gastrointestinal diseases. Metacrine has developed a proprietary farnesoid X receptor (FXR) platform utilizing a unique chemical scaffold, which has demonstrated an improved therapeutic profile in clinical trials. The Company’s two product candidates, MET409 and MET642, are currently being investigated in clinical trials as potential new treatments for NASH. MET409 has completed a 12-week monotherapy trial in patients with NASH and is being evaluated in a 12-week combination trial with empagliflozin in patients with both NASH and type 2 diabetes. MET642 has completed a 14-day Phase 1 trial in healthy volunteers and is being evaluated in a 16-week monotherapy trial in patients with NASH. To learn more, visit www.metacrine.com.

FAQ

What announcement did Metacrine make on August 9, 2021?

Metacrine announced that CEO Preston Klassen will present virtually at the 2021 Canaccord Genuity Growth Conference on August 12, 2021.

When will Metacrine's presentation at the Canaccord Genuity Growth Conference take place?

The presentation is scheduled for August 12, 2021, at 12:30 p.m. ET.

How can I watch Metacrine's presentation at the conference?

A live webcast of Metacrine's presentation will be available, with a replay archived for 90 days.

What is Metacrine's focus in biopharmaceuticals?

Metacrine focuses on developing differentiated therapies for liver and gastrointestinal diseases.

What are Metacrine's lead product candidates for NASH?

Metacrine's lead candidates for NASH are MET409 and MET642, currently in clinical trials.